Christopher DeSouza
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endothelium, Vascular | 44 | 2023 | 907 | 9.160 |
Why?
| Cell-Derived Microparticles | 13 | 2023 | 62 | 7.770 |
Why?
| Vasodilation | 28 | 2023 | 457 | 6.440 |
Why?
| Endothelin-1 | 16 | 2023 | 168 | 5.960 |
Why?
| Vasoconstriction | 13 | 2023 | 213 | 4.200 |
Why?
| Endothelial Cells | 15 | 2023 | 732 | 3.910 |
Why?
| Fibrinolysis | 14 | 2021 | 159 | 3.390 |
Why?
| Hypertension | 13 | 2023 | 1203 | 2.910 |
Why?
| Sleep Deprivation | 6 | 2021 | 164 | 2.900 |
Why?
| Nitric Oxide | 13 | 2023 | 892 | 2.880 |
Why?
| Forearm | 17 | 2021 | 117 | 2.870 |
Why?
| Vasodilator Agents | 20 | 2023 | 328 | 2.710 |
Why?
| Tissue Plasminogen Activator | 15 | 2023 | 231 | 2.610 |
Why?
| Overweight | 9 | 2018 | 502 | 2.470 |
Why?
| Obesity | 19 | 2023 | 2746 | 2.420 |
Why?
| Aging | 36 | 2011 | 1670 | 2.270 |
Why?
| MicroRNAs | 6 | 2023 | 637 | 2.230 |
Why?
| Human Umbilical Vein Endothelial Cells | 6 | 2023 | 95 | 2.200 |
Why?
| Exercise | 31 | 2023 | 1657 | 2.120 |
Why?
| Prehypertension | 5 | 2015 | 27 | 1.890 |
Why?
| Middle Aged | 105 | 2024 | 27617 | 1.860 |
Why?
| Cardiovascular Diseases | 11 | 2021 | 1798 | 1.780 |
Why?
| Acetylcholine | 16 | 2023 | 208 | 1.750 |
Why?
| Regional Blood Flow | 23 | 2023 | 418 | 1.690 |
Why?
| HIV Envelope Protein gp120 | 3 | 2019 | 60 | 1.690 |
Why?
| Sleep | 5 | 2021 | 660 | 1.680 |
Why?
| Blood Pressure | 19 | 2021 | 1664 | 1.600 |
Why?
| Polycythemia | 2 | 2021 | 26 | 1.580 |
Why?
| Stem Cells | 8 | 2012 | 559 | 1.530 |
Why?
| Apoptosis | 14 | 2023 | 2484 | 1.530 |
Why?
| Spinal Cord Injuries | 3 | 2023 | 184 | 1.450 |
Why?
| Nitric Oxide Synthase Type III | 7 | 2023 | 198 | 1.330 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 21 | 1.330 |
Why?
| C-Reactive Protein | 7 | 2015 | 360 | 1.320 |
Why?
| Nitroprusside | 15 | 2021 | 88 | 1.310 |
Why?
| Circulating MicroRNA | 2 | 2019 | 23 | 1.300 |
Why?
| Male | 88 | 2024 | 57801 | 1.280 |
Why?
| Postmenopause | 17 | 2023 | 305 | 1.230 |
Why?
| Atherosclerosis | 2 | 2023 | 345 | 1.220 |
Why?
| Metabolic Syndrome | 4 | 2016 | 394 | 1.220 |
Why?
| Nebivolol | 2 | 2017 | 9 | 1.200 |
Why?
| Cell Movement | 8 | 2014 | 896 | 1.190 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 55 | 1.140 |
Why?
| Peptides, Cyclic | 7 | 2013 | 260 | 1.110 |
Why?
| Caspase 3 | 5 | 2017 | 243 | 1.110 |
Why?
| Humans | 126 | 2024 | 118974 | 1.060 |
Why?
| Vasoconstrictor Agents | 6 | 2023 | 122 | 1.010 |
Why?
| Adult | 63 | 2023 | 31512 | 0.990 |
Why?
| Female | 77 | 2023 | 61565 | 0.940 |
Why?
| Aged | 60 | 2021 | 19657 | 0.900 |
Why?
| Inflammation Mediators | 4 | 2021 | 502 | 0.850 |
Why?
| Dietary Fats | 2 | 2015 | 322 | 0.850 |
Why?
| Blood Coagulation | 2 | 2021 | 219 | 0.840 |
Why?
| Estrogen Replacement Therapy | 9 | 2003 | 117 | 0.790 |
Why?
| Altitude | 3 | 2021 | 422 | 0.780 |
Why?
| Vasomotor System | 1 | 2021 | 47 | 0.770 |
Why?
| Vascular Diseases | 1 | 2023 | 241 | 0.760 |
Why?
| Case-Control Studies | 11 | 2021 | 3171 | 0.720 |
Why?
| Physical Endurance | 15 | 2024 | 231 | 0.720 |
Why?
| Acclimatization | 1 | 2021 | 135 | 0.720 |
Why?
| Hemodynamics | 8 | 2021 | 1004 | 0.710 |
Why?
| Oxidative Stress | 7 | 2021 | 1178 | 0.710 |
Why?
| Telomere | 3 | 2010 | 204 | 0.690 |
Why?
| Ascorbic Acid | 3 | 2021 | 120 | 0.690 |
Why?
| Physical Fitness | 11 | 2005 | 179 | 0.670 |
Why?
| Cells, Cultured | 8 | 2021 | 4077 | 0.670 |
Why?
| T-Lymphocyte Subsets | 2 | 2011 | 396 | 0.660 |
Why?
| Endothelium | 3 | 2020 | 120 | 0.650 |
Why?
| Blood Glucose | 7 | 2019 | 1939 | 0.640 |
Why?
| Hematopoietic Stem Cells | 2 | 2011 | 359 | 0.630 |
Why?
| Metoprolol | 1 | 2017 | 37 | 0.620 |
Why?
| HIV | 1 | 2019 | 210 | 0.620 |
Why?
| Plethysmography | 5 | 2017 | 124 | 0.610 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1945 | 0.610 |
Why?
| Hyperglycemia | 2 | 2018 | 312 | 0.610 |
Why?
| Cross-Sectional Studies | 21 | 2021 | 4552 | 0.600 |
Why?
| HIV Infections | 4 | 2019 | 2459 | 0.590 |
Why?
| Receptor, Endothelin A | 2 | 2014 | 60 | 0.590 |
Why?
| Body Mass Index | 15 | 2017 | 2092 | 0.580 |
Why?
| Cellular Senescence | 1 | 2018 | 151 | 0.580 |
Why?
| Stress, Physiological | 2 | 2017 | 415 | 0.570 |
Why?
| Cytokines | 4 | 2020 | 1900 | 0.570 |
Why?
| Nitric Oxide Synthase | 4 | 2017 | 225 | 0.540 |
Why?
| Bradykinin | 7 | 2015 | 48 | 0.530 |
Why?
| Enzyme Inhibitors | 5 | 2017 | 827 | 0.530 |
Why?
| Gender Identity | 2 | 2006 | 102 | 0.530 |
Why?
| Blood Pressure Determination | 2 | 2016 | 133 | 0.520 |
Why?
| Diet, High-Fat | 2 | 2018 | 247 | 0.490 |
Why?
| Blood Platelets | 1 | 2017 | 369 | 0.480 |
Why?
| Endothelial Progenitor Cells | 1 | 2014 | 18 | 0.480 |
Why?
| Analysis of Variance | 7 | 2016 | 1293 | 0.450 |
Why?
| Infusions, Intra-Arterial | 5 | 2013 | 46 | 0.450 |
Why?
| Biomarkers | 10 | 2021 | 3588 | 0.450 |
Why?
| Adiposity | 3 | 2016 | 516 | 0.450 |
Why?
| Colony-Forming Units Assay | 6 | 2014 | 93 | 0.440 |
Why?
| Anti-HIV Agents | 1 | 2019 | 664 | 0.440 |
Why?
| Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.430 |
Why?
| Blood Vessels | 1 | 2014 | 187 | 0.430 |
Why?
| Alkalosis, Respiratory | 2 | 2023 | 2 | 0.430 |
Why?
| T-Lymphocytes | 2 | 2010 | 1774 | 0.420 |
Why?
| Glucose | 1 | 2017 | 953 | 0.420 |
Why?
| Oxygen Consumption | 11 | 2024 | 586 | 0.420 |
Why?
| Coronary Disease | 3 | 2007 | 356 | 0.420 |
Why?
| Glucose Intolerance | 1 | 2013 | 139 | 0.410 |
Why?
| Fatty Acids | 1 | 2014 | 407 | 0.400 |
Why?
| Time Factors | 10 | 2021 | 6412 | 0.400 |
Why?
| Muscle, Smooth, Vascular | 5 | 2010 | 454 | 0.400 |
Why?
| Risk Factors | 14 | 2018 | 9000 | 0.390 |
Why?
| Abdominal Fat | 1 | 2011 | 48 | 0.390 |
Why?
| Muscle Tonus | 2 | 2010 | 19 | 0.390 |
Why?
| Antigens, CD34 | 1 | 2011 | 98 | 0.390 |
Why?
| HIV Protease Inhibitors | 1 | 2011 | 64 | 0.380 |
Why?
| Body Composition | 13 | 2009 | 653 | 0.370 |
Why?
| HIV-1 | 2 | 2019 | 776 | 0.370 |
Why?
| Cholesterol, LDL | 1 | 2012 | 316 | 0.370 |
Why?
| Dyslipidemias | 1 | 2012 | 162 | 0.370 |
Why?
| Chemotaxis | 1 | 2010 | 137 | 0.360 |
Why?
| Heart Failure | 1 | 2023 | 1969 | 0.360 |
Why?
| Postprandial Period | 3 | 2019 | 96 | 0.360 |
Why?
| Health | 1 | 2010 | 81 | 0.360 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 2008 | 48 | 0.350 |
Why?
| NF-kappa B | 2 | 2023 | 670 | 0.350 |
Why?
| Sleep Wake Disorders | 1 | 2013 | 241 | 0.350 |
Why?
| Flow Cytometry | 4 | 2019 | 1085 | 0.350 |
Why?
| Feeding Behavior | 1 | 2015 | 601 | 0.350 |
Why?
| Disease | 1 | 2010 | 98 | 0.350 |
Why?
| Young Adult | 10 | 2023 | 10793 | 0.330 |
Why?
| Vascular Endothelial Growth Factor A | 4 | 2014 | 527 | 0.330 |
Why?
| Muscarinic Agonists | 1 | 2008 | 10 | 0.320 |
Why?
| Inflammation | 4 | 2020 | 2566 | 0.320 |
Why?
| Fasting | 4 | 2019 | 264 | 0.310 |
Why?
| Reference Values | 7 | 2016 | 774 | 0.300 |
Why?
| Reactive Oxygen Species | 2 | 2021 | 576 | 0.300 |
Why?
| omega-N-Methylarginine | 3 | 2015 | 27 | 0.300 |
Why?
| Endothelin Receptor Antagonists | 4 | 2011 | 59 | 0.300 |
Why?
| Interleukin-6 | 4 | 2021 | 688 | 0.300 |
Why?
| Plasminogen Activator Inhibitor 1 | 5 | 2011 | 82 | 0.290 |
Why?
| Adult Stem Cells | 1 | 2006 | 35 | 0.290 |
Why?
| Epigenesis, Genetic | 1 | 2010 | 539 | 0.270 |
Why?
| Dinucleotide Repeats | 1 | 2005 | 5 | 0.270 |
Why?
| Double-Blind Method | 5 | 2021 | 1687 | 0.270 |
Why?
| Walking | 5 | 2018 | 415 | 0.270 |
Why?
| Hyperthermia, Induced | 2 | 2023 | 67 | 0.270 |
Why?
| Myocardial Ischemia | 1 | 2006 | 251 | 0.260 |
Why?
| Arteries | 6 | 2018 | 250 | 0.250 |
Why?
| Estrogen Receptor alpha | 1 | 2005 | 126 | 0.250 |
Why?
| Blood Flow Velocity | 3 | 2012 | 327 | 0.240 |
Why?
| Antihypertensive Agents | 4 | 2013 | 437 | 0.240 |
Why?
| Age Factors | 8 | 2010 | 2995 | 0.240 |
Why?
| Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.240 |
Why?
| Hypertrophy | 2 | 2023 | 121 | 0.240 |
Why?
| Actinin | 1 | 2023 | 14 | 0.230 |
Why?
| Troponin T | 1 | 2023 | 50 | 0.220 |
Why?
| Running | 5 | 2000 | 227 | 0.210 |
Why?
| Vaping | 1 | 2023 | 51 | 0.210 |
Why?
| Receptor, Endothelin B | 2 | 2014 | 53 | 0.210 |
Why?
| Adipose Tissue | 5 | 2005 | 606 | 0.210 |
Why?
| Electronic Nicotine Delivery Systems | 1 | 2023 | 81 | 0.210 |
Why?
| Sex Characteristics | 4 | 2017 | 671 | 0.210 |
Why?
| Breathing Exercises | 1 | 2021 | 22 | 0.200 |
Why?
| Inhalation | 1 | 2021 | 27 | 0.200 |
Why?
| Respiratory Muscles | 1 | 2021 | 36 | 0.200 |
Why?
| South America | 1 | 2021 | 56 | 0.200 |
Why?
| Peru | 1 | 2021 | 59 | 0.200 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 31 | 0.200 |
Why?
| Lymphocyte Count | 2 | 2011 | 136 | 0.190 |
Why?
| Healthy Lifestyle | 1 | 2021 | 33 | 0.190 |
Why?
| Transcription Factor RelA | 1 | 2021 | 82 | 0.190 |
Why?
| Endothelins | 1 | 2021 | 62 | 0.190 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2019 | 2174 | 0.190 |
Why?
| Carotid Arteries | 4 | 2003 | 184 | 0.190 |
Why?
| Drug Administration Schedule | 2 | 2016 | 736 | 0.190 |
Why?
| Fibrosis | 1 | 2023 | 483 | 0.190 |
Why?
| Transforming Growth Factor beta | 1 | 2023 | 462 | 0.180 |
Why?
| Cytochromes c | 2 | 2010 | 64 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2015 | 1171 | 0.180 |
Why?
| Chemokine CXCL12 | 2 | 2010 | 80 | 0.180 |
Why?
| Piperidines | 2 | 2013 | 171 | 0.180 |
Why?
| Interleukin-8 | 1 | 2021 | 249 | 0.180 |
Why?
| Fibrinogen | 2 | 1998 | 161 | 0.180 |
Why?
| Oligopeptides | 2 | 2013 | 252 | 0.180 |
Why?
| Fever | 2 | 2020 | 283 | 0.180 |
Why?
| Insulin Glargine | 1 | 2019 | 72 | 0.170 |
Why?
| Colorado | 5 | 2021 | 4196 | 0.170 |
Why?
| Physical Exertion | 2 | 1998 | 222 | 0.170 |
Why?
| Cell Proliferation | 1 | 2006 | 2275 | 0.170 |
Why?
| Risk Reduction Behavior | 1 | 2021 | 199 | 0.170 |
Why?
| E-Selectin | 1 | 2018 | 52 | 0.170 |
Why?
| HIV Antibodies | 1 | 2019 | 50 | 0.170 |
Why?
| Hemoglobins | 1 | 2021 | 326 | 0.170 |
Why?
| Infusions, Intravenous | 2 | 2011 | 380 | 0.170 |
Why?
| Telomerase | 2 | 2011 | 207 | 0.170 |
Why?
| Myocytes, Cardiac | 1 | 2023 | 472 | 0.170 |
Why?
| Phenotype | 2 | 2021 | 3003 | 0.170 |
Why?
| Brachial Artery | 3 | 2017 | 181 | 0.160 |
Why?
| Heat-Shock Response | 1 | 2018 | 59 | 0.160 |
Why?
| Pilot Projects | 1 | 2023 | 1419 | 0.160 |
Why?
| Follow-Up Studies | 3 | 2017 | 4596 | 0.160 |
Why?
| Treatment Outcome | 5 | 2021 | 9342 | 0.160 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 9 | 0.160 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 42 | 0.160 |
Why?
| Myocardial Infarction | 1 | 2005 | 968 | 0.160 |
Why?
| Exercise Therapy | 3 | 2017 | 355 | 0.160 |
Why?
| Lipids | 3 | 2009 | 607 | 0.160 |
Why?
| Antioxidants | 1 | 2021 | 564 | 0.160 |
Why?
| Dietary Carbohydrates | 1 | 2018 | 153 | 0.150 |
Why?
| Heart | 1 | 2021 | 631 | 0.150 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 175 | 0.150 |
Why?
| Prognosis | 3 | 2018 | 3443 | 0.150 |
Why?
| Infusions, Intraosseous | 1 | 2016 | 19 | 0.140 |
Why?
| Anthropometry | 2 | 2011 | 194 | 0.140 |
Why?
| Triglycerides | 3 | 2005 | 519 | 0.140 |
Why?
| Phosphorylation | 1 | 2020 | 1633 | 0.130 |
Why?
| Enzyme Activation | 1 | 2017 | 828 | 0.130 |
Why?
| Substance P | 2 | 2008 | 44 | 0.130 |
Why?
| Hot Temperature | 1 | 2017 | 334 | 0.130 |
Why?
| Isoproterenol | 2 | 2008 | 125 | 0.130 |
Why?
| Blood Circulation | 1 | 2015 | 36 | 0.130 |
Why?
| Down-Regulation | 1 | 2017 | 627 | 0.130 |
Why?
| Cross-Over Studies | 4 | 2017 | 456 | 0.130 |
Why?
| Interleukin-18 | 2 | 2006 | 228 | 0.120 |
Why?
| Peptides | 1 | 2019 | 879 | 0.120 |
Why?
| Signal Transduction | 3 | 2014 | 4709 | 0.120 |
Why?
| Hydrocortisone | 1 | 2015 | 273 | 0.110 |
Why?
| Interleukin-10 | 1 | 2015 | 306 | 0.110 |
Why?
| Regression Analysis | 4 | 2011 | 983 | 0.110 |
Why?
| Hypoglycemic Agents | 1 | 2019 | 1032 | 0.100 |
Why?
| Cholinergic Agonists | 1 | 2011 | 6 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 210 | 0.100 |
Why?
| Blood Volume | 4 | 1999 | 58 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2015 | 401 | 0.100 |
Why?
| Plaque, Atherosclerotic | 1 | 2011 | 40 | 0.100 |
Why?
| Obesity, Abdominal | 1 | 2011 | 39 | 0.100 |
Why?
| Waist Circumference | 1 | 2011 | 130 | 0.100 |
Why?
| Prevalence | 3 | 2014 | 2326 | 0.100 |
Why?
| Vital Capacity | 2 | 2002 | 260 | 0.100 |
Why?
| Femoral Artery | 2 | 2002 | 175 | 0.090 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2011 | 190 | 0.090 |
Why?
| Plant Lectins | 1 | 2010 | 8 | 0.090 |
Why?
| Cholesterol | 2 | 2005 | 373 | 0.090 |
Why?
| Staurosporine | 1 | 2010 | 23 | 0.090 |
Why?
| Cerebrovascular Circulation | 2 | 2023 | 204 | 0.090 |
Why?
| Estrogens | 2 | 2003 | 328 | 0.090 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 70 | 0.090 |
Why?
| Bone Diseases, Metabolic | 1 | 2010 | 60 | 0.090 |
Why?
| CD3 Complex | 1 | 2009 | 92 | 0.090 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 195 | 0.090 |
Why?
| Cell Separation | 1 | 2010 | 296 | 0.090 |
Why?
| Leg | 2 | 2001 | 234 | 0.090 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 341 | 0.090 |
Why?
| Baroreflex | 2 | 2000 | 53 | 0.090 |
Why?
| Norepinephrine | 1 | 2009 | 212 | 0.080 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 420 | 0.080 |
Why?
| Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| Aspartic Acid Endopeptidases | 1 | 2008 | 22 | 0.080 |
Why?
| Up-Regulation | 1 | 2012 | 872 | 0.080 |
Why?
| Metalloendopeptidases | 1 | 2008 | 56 | 0.080 |
Why?
| Methacholine Chloride | 1 | 2008 | 48 | 0.080 |
Why?
| Cell Count | 1 | 2008 | 315 | 0.080 |
Why?
| Calcium Channel Blockers | 1 | 2008 | 117 | 0.080 |
Why?
| Life Style | 4 | 2003 | 430 | 0.080 |
Why?
| Hemiplegia | 2 | 1997 | 19 | 0.080 |
Why?
| Coronary Circulation | 1 | 2007 | 121 | 0.070 |
Why?
| Arm | 1 | 2007 | 106 | 0.070 |
Why?
| Risk Assessment | 1 | 2016 | 3057 | 0.070 |
Why?
| Probability | 1 | 2007 | 305 | 0.070 |
Why?
| Lipoproteins, LDL | 1 | 2006 | 138 | 0.070 |
Why?
| Muscle, Skeletal | 3 | 2002 | 1515 | 0.070 |
Why?
| Microscopy, Phase-Contrast | 1 | 2005 | 19 | 0.070 |
Why?
| DNA Methylation | 1 | 2010 | 503 | 0.070 |
Why?
| Aged, 80 and over | 5 | 2003 | 6561 | 0.070 |
Why?
| Thymidine | 1 | 2005 | 62 | 0.070 |
Why?
| Weight Loss | 1 | 2010 | 655 | 0.060 |
Why?
| Bone Marrow Cells | 1 | 2005 | 273 | 0.060 |
Why?
| Thrombosis | 1 | 2007 | 309 | 0.060 |
Why?
| Anaerobic Threshold | 2 | 2005 | 21 | 0.060 |
Why?
| France | 1 | 2024 | 35 | 0.060 |
Why?
| Hypocapnia | 1 | 2023 | 5 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 387 | 0.060 |
Why?
| Hyperventilation | 1 | 2023 | 8 | 0.060 |
Why?
| Adenine | 1 | 2005 | 223 | 0.060 |
Why?
| Oxidation-Reduction | 1 | 2006 | 940 | 0.060 |
Why?
| Bicycling | 1 | 2024 | 77 | 0.060 |
Why?
| Fenofibrate | 1 | 2003 | 24 | 0.060 |
Why?
| Muscarinic Antagonists | 1 | 2003 | 25 | 0.060 |
Why?
| Hypertriglyceridemia | 1 | 2003 | 39 | 0.060 |
Why?
| Body Weight | 2 | 2005 | 934 | 0.060 |
Why?
| Physical Education and Training | 1 | 2003 | 62 | 0.060 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 1795 | 0.050 |
Why?
| Exercise Test | 3 | 2005 | 551 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2005 | 642 | 0.050 |
Why?
| Carotid Artery Diseases | 1 | 2002 | 58 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 230 | 0.050 |
Why?
| Progesterone | 1 | 2003 | 242 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 132 | 0.050 |
Why?
| Tunica Intima | 4 | 2002 | 78 | 0.050 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2000 | 40 | 0.050 |
Why?
| Knee | 1 | 2000 | 52 | 0.050 |
Why?
| Heart Rate | 3 | 1998 | 729 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2005 | 1868 | 0.050 |
Why?
| Compliance | 3 | 2008 | 44 | 0.040 |
Why?
| Oxygen | 1 | 2024 | 854 | 0.040 |
Why?
| Social Class | 1 | 2001 | 218 | 0.040 |
Why?
| Hemorheology | 1 | 2018 | 20 | 0.040 |
Why?
| Energy Intake | 2 | 1998 | 447 | 0.040 |
Why?
| Drug Combinations | 1 | 2019 | 291 | 0.040 |
Why?
| Body Constitution | 1 | 1998 | 47 | 0.040 |
Why?
| Diet, Fat-Restricted | 1 | 2018 | 76 | 0.040 |
Why?
| Hemostasis | 1 | 1998 | 70 | 0.040 |
Why?
| Microvessels | 1 | 2018 | 77 | 0.040 |
Why?
| Premenopause | 4 | 1999 | 108 | 0.040 |
Why?
| United States | 1 | 2014 | 12555 | 0.040 |
Why?
| Cervical Vertebrae | 1 | 2018 | 115 | 0.040 |
Why?
| Plasminogen Activators | 1 | 1997 | 8 | 0.040 |
Why?
| Fibrin Fibrinogen Degradation Products | 1 | 1998 | 79 | 0.040 |
Why?
| Ultrasonography | 4 | 2002 | 716 | 0.040 |
Why?
| Gait | 2 | 1997 | 253 | 0.040 |
Why?
| Vascular Resistance | 1 | 1998 | 356 | 0.040 |
Why?
| Cohort Studies | 1 | 2007 | 5116 | 0.040 |
Why?
| Movement Disorders | 1 | 1997 | 45 | 0.040 |
Why?
| Cerebrovascular Disorders | 1 | 1997 | 86 | 0.040 |
Why?
| Chromium | 1 | 1996 | 12 | 0.030 |
Why?
| Neoplasms | 1 | 2010 | 2179 | 0.030 |
Why?
| Weight Lifting | 1 | 1996 | 30 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2018 | 509 | 0.030 |
Why?
| Hypoxia | 1 | 2021 | 963 | 0.030 |
Why?
| Insulin | 1 | 2005 | 2162 | 0.030 |
Why?
| Antigens | 1 | 1996 | 320 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2017 | 1166 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1244 | 0.030 |
Why?
| Swimming | 3 | 1999 | 46 | 0.030 |
Why?
| Menopause | 1 | 1997 | 266 | 0.030 |
Why?
| Melatonin | 1 | 2015 | 109 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 1997 | 299 | 0.030 |
Why?
| Brain Ischemia | 1 | 1997 | 310 | 0.030 |
Why?
| Tunica Media | 2 | 2001 | 36 | 0.020 |
Why?
| Sex Factors | 1 | 1996 | 1781 | 0.020 |
Why?
| Brain | 1 | 2020 | 2490 | 0.020 |
Why?
| Cardiac Output | 2 | 1998 | 147 | 0.020 |
Why?
| Prospective Studies | 4 | 2001 | 6471 | 0.020 |
Why?
| Bone Density | 1 | 2010 | 449 | 0.020 |
Why?
| Stroke Volume | 2 | 1998 | 513 | 0.020 |
Why?
| Hemostatics | 1 | 2005 | 50 | 0.020 |
Why?
| Adolescent | 5 | 2002 | 18480 | 0.020 |
Why?
| Hypolipidemic Agents | 1 | 2003 | 86 | 0.010 |
Why?
| Fatty Acids, Nonesterified | 1 | 2003 | 167 | 0.010 |
Why?
| Lipoproteins | 1 | 2003 | 162 | 0.010 |
Why?
| Absorptiometry, Photon | 1 | 2002 | 229 | 0.010 |
Why?
| Blood Viscosity | 1 | 2001 | 19 | 0.010 |
Why?
| Habits | 1 | 2001 | 38 | 0.010 |
Why?
| Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| Thigh | 1 | 2000 | 56 | 0.010 |
Why?
| Mexico | 1 | 2001 | 165 | 0.010 |
Why?
| Thinness | 1 | 2000 | 91 | 0.010 |
Why?
| Elasticity | 1 | 2000 | 193 | 0.010 |
Why?
| Erythrocyte Volume | 1 | 1999 | 4 | 0.010 |
Why?
| Plasma Volume | 1 | 1999 | 13 | 0.010 |
Why?
| Femur | 1 | 2001 | 199 | 0.010 |
Why?
| Stress, Mechanical | 1 | 2001 | 443 | 0.010 |
Why?
| Supine Position | 1 | 1998 | 39 | 0.010 |
Why?
| Posture | 1 | 1999 | 158 | 0.010 |
Why?
| Signal Processing, Computer-Assisted | 1 | 1998 | 140 | 0.010 |
Why?
| Hematocrit | 1 | 1997 | 91 | 0.010 |
Why?
| Rest | 1 | 1997 | 104 | 0.010 |
Why?
| Electric Conductivity | 1 | 1997 | 91 | 0.010 |
Why?
| Ventricular Fibrillation | 1 | 1997 | 51 | 0.010 |
Why?
| Electrodes, Implanted | 1 | 1997 | 97 | 0.010 |
Why?
| Hyperlipidemias | 1 | 1997 | 128 | 0.010 |
Why?
| Diabetes Complications | 1 | 1997 | 218 | 0.010 |
Why?
| Tachycardia, Ventricular | 1 | 1997 | 151 | 0.010 |
Why?
| Electrocardiography | 1 | 1998 | 556 | 0.010 |
Why?
| Equipment Design | 1 | 1997 | 519 | 0.010 |
Why?
| Multivariate Analysis | 1 | 1998 | 1474 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1180 | 0.010 |
Why?
| Kinetics | 1 | 1997 | 1624 | 0.010 |
Why?
| Animals | 2 | 2008 | 33381 | 0.010 |
Why?
| Stroke | 1 | 2002 | 1047 | 0.010 |
Why?
| Heart Arrest | 1 | 1997 | 291 | 0.010 |
Why?
| Survival Rate | 1 | 1997 | 1720 | 0.010 |
Why?
| Length of Stay | 1 | 1997 | 1032 | 0.010 |
Why?
| Energy Metabolism | 1 | 1997 | 767 | 0.010 |
Why?
| Smoking | 1 | 1997 | 1487 | 0.010 |
Why?
| Retrospective Studies | 1 | 2003 | 12978 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|